Aclarubicin hydrochloride - CAS 75443-99-1
Catalog number: 75443-99-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C42H54ClNO15
Molecular Weight:
848.336
COA:
Inquire
Description:
aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for active clinical trials or closed clinical trials using this agent.
Purity:
>98%
Synonyms:
aclacinomycin; Aclacinomycin A; Aclacinomycin A hydrochloride; aclacinomycin-A; Aclarubicin Hydrochloride; Antibiotic MA144-A1. Aclacin; Aclacinomycine; Aclacinon; Aclaplastin; Jaclacin. ACM; ACM-A. MA144-A1
MSDS:
Inquire
InChIKey:
KUSMIBXCRZTVML-PCCPLWKKSA-N
InChI:
InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1
Canonical SMILES:
CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O.Cl
1.The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
Tsuda T1, Okamoto Y, Sakaguchi R, Katayama N, Ota K. J Int Med Res. 2001 Jan-Feb;29(1):41-7.
Elderly patients with acute myelomonocytic leukaemia (AMMoL) frequently have a poor quality of life after induction of remission using high-intensity treatment; we seek a more appropriate regimen for such patients. An 86-year-old man was hospitalized with a diagnosis of AMMoL (FAB classification M4), of abnormal karyotype, and complications of diabetes mellitus and complete right bundle branch block. He was treated with CAG therapy (cytarabine 10 mg/m2 subcutaneously every 12 h for 14 consecutive days; aclarubicin hydrochloride 10 mg/m2 per day, bolus intravenously for 4 consecutive days; granulocyte colony-stimulating factor 100 microg/day, subcutaneous injection for 14 consecutive days) every 3 months. White blood cell counts were at their lowest (around 600 - 800/microl) 12 days after the end of therapy, but returned to about 2000 - 2300/microl 30 days after stopping therapy. No symptoms of drug-related toxicity, except slight nausea, were found.
2.Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride.
Ichihara T1, Sakamoto K, Mori K, Akagi M. Cancer Res. 1989 Aug 1;49(15):4357-62.
Transcatheter arterial chemoembolization therapy using polylactic acid microspheres containing aclarubicin hydrochloride (ACR) was performed in 62 patients with primary hepatocellular carcinoma. These microspheres were about 200 microns in diameter and contained 10% (w/w) aclarubicin. A single dose of polylactic acid microspheres containing ACR (50-100 mg of ACR) was administered 1 to 8 times with a mean of 2.2 doses (a total of 160 treatments) in 62 patients. Antitumor effects were observed from the decrease in serum alpha-fetoprotein levels (82.1% of the patients) and in two dimensional size of tumor on computed tomography (93.6%). The cumulative survival rate was 54.3% at 1 year, 24.6% at 2 years, and 19.2% at 3 years, respectively, among 59 patients with unresectable tumors. In 3 resected liver specimens, there was a significant accumulation of ACR in the tumor, and severe necroses of the tumors were observed histologically. Systemic toxicity was mild and all patients tolerated this treatment.
3.Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochloride.
Kawashima O1, Kurihara T, Kamiyoshihara M, Sakata S, Ishikawa S, Morishita Y. Am J Clin Oncol. 1999 Aug;22(4):396-8.
To determine the efficacy of aclarubicin hydrochloride in local control of malignant pericardial effusion, the authors carried out a trial of pericardial drainage with local administration of this agent in five patients, whose effusions had produced cardiac tamponade. All patients were women, and their primary cancers, all initially treated surgically, had arisen in the breast (two patients), or lung (three patients). Mean patient age was 54.2 years (range, 43-62). In four patients, improvement permitted removal of the drainage catheter. Two patients (40%) had a complete remission of the malignant pericardial effusion. The other three patients were difficult to evaluate because nonpericardial metastases limited their survival. All patients, however, showed disappearance of malignant cells from the pericardial sac with no cytopathologically demonstrable recurrence. In our few patients, intrapericardial aclarubicin appeared to be highly effective against malignant pericardial effusion.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 887650-05-7 Bafetinib

Bafetinib
(CAS: 887650-05-7)

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...

CAS 894787-30-5 ST 2825

ST 2825
(CAS: 894787-30-5)

ST 2825 is a MyD88 pharmacologic inhibitor. It inhibited MyD88 dimerization in coimmunoprecipitation experiments. It interfered with recruitment of IRAK1 and IR...

CAS 346688-38-8 Pridopidine

Pridopidine
(CAS: 346688-38-8)

Pridopidine, also known as ACR16, is a dopamine stabilizer used in the treatment of neurologic and psychiatric disorders.

Palifosfamide tromethamine
(CAS: 1070409-31-2)

Palifosfamide tromethamine is a synthetic mustard compound with potential antineoplastic activity. It is an active metabolite of ifosfamide covalently linked to...

CAS 518-28-5 Podophyllotoxin

Podophyllotoxin
(CAS: 518-28-5)

Podophyllotoxin, a kind of non-alkaloid toxin lignan extracted from the roots and rhizomes of Podophyllum plant, has been shown to inhibit the growth of various...

CAS 109140-45-6 3-(Dipropylamino)-3,4-dihydro-2H-1-benzopyran-8-ol hydrochloride

3-(Dipropylamino)-3,4-dihydro-2H-1-benzo
(CAS: 109140-45-6)

A dopamine receptor agonist.

SGI-7079
(CAS: 1239875-86-5)

This active molecular is a selective Axl inhibitor and Axl is a potential therapeutic target for overcoming EGFR inhibitor resistance. SGI-7079 significantly in...

CAS 1227939-82-3 Ilorasertib

Ilorasertib
(CAS: 1227939-82-3)

Ilorasertib, also know as ABT-348, is a novel, potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor ...

Chemical Structure

CAS 75443-99-1 Aclarubicin hydrochloride

Quick Inquiry

Verification code

Featured Items